Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AKGPX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TW202444426A ADC-031
|
|||||
| Synonyms |
TW202444426A ADC-031
Click to Show/Hide
|
|||||
| Organization |
EXELIXIS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-mAb304
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC | 881.76 nM | Positive XXX expression (XXX+++/++) | ||
| Method Description |
The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
|
||||
| In Vitro Model | Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary | COV434-AMRH2 cells | CVCL_2010 | ||